BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Entod Pharma develops world's first human insulin eye drops

14 March 2024 | News

Company's next step involves initiating the drug regulatory approval process in India



Mumbai-based Entod Pharmaceuticals has pioneered the development of the world's first human insulin eye drops designed to treat corneal eye conditions like neurotrophic corneal ulcers and dry eyes.

Although Insulin has traditionally been administered through injections to manage blood sugar levels in diabetic patients globally, recent research from various global studies has demonstrated its potential effectiveness when applied as eye drops. These findings suggest that insulin eye drops can aid in repairing corneal tissue and addressing ocular surface conditions.

The company's next step involves initiating the drug regulatory approval process in India. This will begin with an application to the Central Drugs Standard Control Organisation (CDSCO) for approval to conduct clinical trials of these eye drops. Subsequently, the company will seek approval from the *Drugs Controller General of India* (DCGI) for commercialisation.

According to Nikkhil K Masurkar, CEO, Entod Pharma, "There is compelling and growing global evidence suggesting that insulin eye drops could revolutionise ophthalmic therapeutics. Our eye drop formulation, EyeSulin, would be the first of its kind in the world to treat eye conditions once approved. Upon regulatory clearance, we aim to produce these eye drops as part of the 'Make in India' initiative, making them accessible across India and globally at an affordable price."

Last year, the company achieved a significant milestone by becoming the first in India to develop an eye drop called PresVu. This innovative product aims to address presbyopia, offering a potential alternative to reading glasses for millions. Following successful completion of phase 3 clinical trials in India, PresVu is poised for commercialisation pending approval from DCGI in the first quarter of the financial year 2024-2025.